Sinotherapeutics Inc. (SHA:688247)
China · Delayed Price · Currency is CNY 8.26
-0.10 (-1.20%)
Jul 29, 2026, 4:00 PM EDT
Sinotherapeutics Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 432.19 | 446.57 | 511.62 | 299.87 | 247.56 | 315.47 |
Revenue Growth | -15.11% | -12.72% | 70.61% | 21.13% | -21.53% | -1.16% |
Gross Profit Gross Profit Growth | 153.95 | 160.59 | 265.51 | 166.37 | 179.12 | 245.03 |
Operating Income Operating Income Growth | 27.98 | 34.62 | 119.48 | 44.3 | 58.21 | 95.1 |
Net Income Net Income Growth | 43.56 | 47.48 | 127.7 | 61.07 | 92.93 | 134.92 |
Earnings Per Share EPS Growth | 0.10 | 0.11 | 0.28 | 0.13 | 0.22 | 0.33 |
EPS Growth | -64.33% | -60.71% | 115.39% | -40.91% | -33.33% | 10.00% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
China China Growth | 316.39 |
Overseas Overseas Growth | 129.66 |
Total Total Growth | 446.05 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 777.34 | 746.45 | 733.53 | 749 | 807.23 | 511.66 |
Total Debt Total Debt Growth | 0.01 | 0.02 | 0.01 | 0.09 | 1.52 | 4.44 |
Net Cash (Debt) Net Cash Growth | 777.33 | 746.43 | 733.53 | 748.92 | 805.71 | 507.22 |
Net Cash Growth | 5.99% | 1.76% | -2.05% | -7.05% | 58.85% | 16.82% |
Net Cash Per Share Net Cash Per Share Growth | 1.80 | 1.73 | 1.61 | 1.59 | 1.91 | 1.24 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 69.92 | 95.33 | 130.23 | 12.96 | 73.18 | 145.77 |
Capital Expenditures CapEx Growth | -31.34 | -41.56 | -94.93 | -38.96 | -176.34 | -16.01 |
Free Cash Flow Free Cash Flow Growth | 38.58 | 53.77 | 35.3 | -26 | -103.15 | 129.77 |
Free Cash Flow Growth | -38.92% | 52.32% | - | - | - | -24.42% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 35.62% | 35.96% | 51.90% | 55.48% | 72.35% | 77.67% |
Operating Margin | 6.48% | 7.75% | 23.35% | 14.77% | 23.51% | 30.14% |
Pretax Margin | 11.21% | 11.94% | 27.77% | 22.01% | 39.37% | 47.24% |
Profit Margin | 10.08% | 10.63% | 24.96% | 20.37% | 37.54% | 42.77% |
FCF Margin | 8.93% | 12.04% | 6.90% | -8.67% | -41.67% | 41.13% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.035 | 0.035 | 0.062 | 0.041 | 0.062 |
Dividend Per Share Growth | -43.55% | -43.55% | 51.22% | -33.87% | - |
Dividend Yield | 0.42% | 0.36% | 0.62% | 0.38% | 0.38% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 82.06 | 91.73 | 35.37 | 81.50 | 81.71 | - |
P/FCF Ratio | 96.14 | 81.00 | 127.97 | - | - | - |
PS Ratio | 8.58 | 9.75 | 8.83 | 16.60 | 30.67 | - |